-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61

Benzinga·11/06/2026 23:14:05
Listen to the news
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $90 to $61.